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Abstract
Background: Obstructive sleep apnea (OSA) and insomnia are frequent sleep problems that are associated with
poor prognosis in patients with coronary heart disease. The mechanisms linking poor sleep with an increased
cardiovascular risk are incompletely understood. We examined whether a high risk of OSA as well as insomnia
symptoms are associated with neuroendocrine hormones and coagulation factors in patients admitted with acute
myocardial infarction.
Methods: We assessed 190 patients (mean age 60 years, 83% men) in terms of OSA risk (STOP screening tool for
the assessment of high vs. low OSA risk) and severity of insomnia symptoms (Jenkins Sleep Scale for the assessment of
subjective sleep difficulties) within 48 h of an acute coronary intervention. Circulating concentrations of epinephrine,
norepinephrine, cortisol, fibrinogen, D-dimer, and von Willebrand factor were measured the next morning. The
association of OSA risk and insomnia symptoms with neuroendocrine hormones and coagulation factors was
computed using multivariate models adjusting for demographic factors, health behaviors, somatic and psychiatric
comorbidities, cardiac disease-related variables, and OSA risk in the model for insomnia symptoms, respectively, for
insomnia symptoms in the model for OSA risk.
Results: High OSA risk was identified in 41% of patients and clinically relevant insomnia symptoms were reported by 27%
of patients. Compared to those with low OSA risk, patients with high OSA risk had lower levels of epinephrine (p= 0.015),
norepinephrine (p= 0.049) and cortisol (p= 0.001). More severe insomnia symptoms were associated with higher levels of
fibrinogen (p= 0.037), driven by difficulties initiating sleep, and with lower levels of norepinephrine (p= 0.024), driven by
difficulties maintaining sleep.
Conclusions: In patients with acute myocardial infarction, sleep problems are associated with neuroendocrine hormones
and coagulation activity. The pattern of these relationships is not uniform for patients with a high risk of OSA and those
with insomnia symptoms, and whether they contribute to adverse cardiovascular outcomes needs to be established.
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Background
Obstructive sleep apnea (OSA) is a common sleep-related
breathing disorder that is caused by repeated upper airway
obstruction during sleep and characterized through symp-
toms of snoring, breathing cessations while sleeping, and
daytime sleepiness and fatigue [1]. Insomnia disorders are
characterized by subjective sleep initiating and maintain-
ing problems in spite of adequate circumstances to sleep
and daytime impairment, whereas insomnia symptoms
alone do not merit a formal diagnosis of insomnia [2].
Obstructive sleep apnea and insomnia symptoms,
including difficulty initiating sleep, difficulty maintaining
sleep and non-restorative sleep, have been associated
with an increased risk of incident coronary heart disease
(CHD) events, independently of a range of other risk
factors [3–7]. Sleep problems may also be associated
with poor prognosis of CHD. In two meta-analyses,
CHD patients with OSA had an almost two-fold higher
risk of poor cardiovascular prognosis, including recur-
rent CHD events and stroke, than CHD patients without
OSA [8, 9]. In terms of insomnia symptoms in patients
with acute myocardial infarction (MI), not feeling
well-rested was predictive of case fatality in the 4 weeks
post-MI in men and of 10-year risk of new CVD events
in women [10]. In women, assessed 3–6 months after
acute coronary syndrome (ACS), a sleep quality index,
defined by insomnia symptoms was a predictor of recur-
rent CHD events at 5-year follow-up, after controlling
for CVD risk factors and depressive symptoms [11]. In
men who had undergone percutaneous coronary angio-
plasty, a state of vital exhaustion, characterized by sub-
jective sleep disturbances, including troubles falling
asleep, waking up repeatedly during the night, and not
feeling well rested, along with profound feelings of
fatigue, was predictive of new CHD events after a
follow-up of 1.5 years [12].
Different biological mechanisms, initiated by intermit-
tent hypoxia, are thought to underpin the association of
OSA with an increased risk of incident CHD, including
sympathetic hyperactivity, systemic inflammation, oxida-
tive stress, vascular endothelial dysfunction, and hyperco-
agulability [13, 14]. Likewise, sympathetic hyperactivity
and systemic inflammation, but also elevated cortisol
(COR) levels have been proposed to be biological mecha-
nisms potentially linking insomnia with incident CVD
[15]. Although these mechanisms might also link poor
sleep with recurrent atherothrombotic events in patents
with established CHD, this has not systematically been
explored. In the present study, we focused on circulating
neuroendocrine and coagulation markers in patients with
sleep problems admitted with acute MI, as sleep studies in
individuals without CVD suggest a role of neuroendocrine
changes and coagulation activation in incident athero-
thrombotic events. For instance, in middle-aged and
elderly subjects, objective sleep problems, including
greater apnea-hypopnea index and oxygen desaturation,
indicating OSA, as well as poor subjective sleep quality,
were associated with increased plasma levels of fibrinogen,
D-dimer, and von Willebrand factor (VWF) [16–20]. In
patients with ACS, these prothrombotic markers were of
prognostic value for major cardiovascular events and
all-cause mortality [21–24].
In OSA, hyperactivity of the sympathetic nervous system
(SNS) is evidenced by increased norepinephrine (NEPI)
turnover [25], whereas findings on hypothalamic-pituitary
adrenal (HPA) axis function, including COR levels, are
contradictory [26]. In insomnia, HPA axis dysregulation is
evidenced by high COR levels in the evening, affecting sleep
architecture [27], and low morning COR levels, which re-
late to poor sleep quality, nightly awakenings and unre-
freshing sleep [28]. The metabolic consequences of
neuroendocrine dysregulation include hypertension, dyslip-
idemia, obesity, diabetes and a prothrombotic state, which
are associated with the progression of atherothrombotic
disease [29]. Secretion of epinephrine (EPI), NEPI, and
COR has effects on coagulation, including increases in
fibrinogen, D-dimer and VWF levels [30, 31], and neuroen-
docrine dysregulation might partially account for a link
between sleep problems and coagulation activity [17].
Insomnia and OSA are often found together in the
same patient, with up to 50% of OSA patients having
insomnia symptoms; a similar prevalence of at least mild
OSA is found in patients with insomnia [32]. However,
in meta-analyses of prospective studies incident and
recurrent CVD risk were not adjusted for the other sleep
disorder nor were joint effects investigated [3–9]. As yet,
except for hypertension [33], there is little evidence that
OSA and insomnia together are associated with a greater
risk of CVD or frequency of CVD risk factors than OSA
alone [34]. However, such studies are still few in number
and, to our knowledge, researchers did not investigate
neuroendocrine and coagulation activity.
In this study we aimed to examine the association of a
high risk of OSA and insomnia symptoms, independ-
ently of each other, with neuroendocrine hormones and
coagulation factors in patients with acute MI. We specif-
ically hypothesized that more sleep problems would be
associated with higher levels of fibrinogen, D-dimer and
VWF. We specified no a priori hypothesis regarding the
direction of an association of sleep problems with EPI,
NEPI and COR levels; this is because findings vary
across studies, depending upon circadian factors, natural
vs. experimental designs, confounding variables, and
measures of sleep quantity and quality [26, 35, 36]. We
predicted the hypothesized relationships to be independ-
ent of demographics, comorbidity, health behaviors, and
cardiac-related variables. In complementary analyses we
examined whether neuroendocrine hormones may account
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for the relation between sleep problems and coagulation
factors, and whether there were joint effects of OSA risk
and insomnia symptoms for neuroendocrine and coagula-
tion outcomes.
Methods
Study participants and design
Rationale of the parent study
Data for this ancillary sleep study were collected from pa-
tients who participated in the Myocardial Infarction-Stress
Prevention Intervention (MI-SPRINT) randomized con-
trolled trial [37]. The primary aim of the parent study was
to test whether a psychological first aid approach (i.e., one
single 45-min session of psychological counseling at hos-
pital referral) may prevent the incidence of ACS-induced
posttraumatic stress at 3-month follow-up [37]. About
12% of ACS patients develop clinically significant levels of
posttraumatic stress which is a predictor of poor cardiac
prognosis [38]. Disrupted sleep could be one mechanism
to explain this link [39]. The overarching hypothesis was
that patients undergoing trauma-focused counseling
would show better mental and physical health, including
sleep, at follow-up than patients undergoing general stress
counseling [37]. The intervention was not considered for
the present study, as it showed no significant association
with sleep, neuroendocrine and coagulation outcomes at
hospital admission.
Patient recruitment
In brief, for MI-SPRINT, we recruited 190 patients with
verified acute ST-elevation MI (STEMI) or non-STEMI
and referred for acute coronary care intervention to the
Bern University Hospital (“Inselspital”) between January
2013 and September 2015. The diagnostic criteria and
therapy for acute STEMI and non-STEMI followed the
European Society of Cardiology guidelines on myocar-
dial revascularization, including indications for primary
percutaneous coronary intervention in non-STEMI,
antithrombotic treatments, and treatments to establish
stable hemodynamic conditions [40, 41]. Inclusion cri-
teria were 18 years or older, stable hemodynamic condi-
tions, and a high level of acute distress during MI
defined by scores of at least 5 for chest pain plus at
least 5 for fear of dying and/or helplessness on numeric
rating scales from 0 to 10 [37]. Exclusion criteria were
emergency coronary artery bypass grafting, comorbid
diseases likely to cause death within 1 year, cognitive
impairment, severe clinical depression, suicidal idea-
tions in the prior 2 weeks, inadequate knowledge of
German, or participation in another trial. The study
protocol was approved by the ethics committee of the
State of Bern (KEK-Nr. 170/12). All patients were
informed and gave signed consent.
Data collection
Within 48 h after having reached stable hemodynamic
conditions, all included patients underwent a struc-
tured clinical interview on the coronary care unit on
which occasion a medical history, sleep-related data
and information on health behaviors were collected.
To limit patient burden in this acute clinical setting,
we decided to assess sleep problems with just two
short screening tools, one to rate OSA risk, and one
to rate the severity of sleep difficulties in terms of
insomnia symptoms (see below). Cardiac-related vari-
ables were additionally abstracted from hospital
charts. Fasting venous blood samples were collected
for the measurement of neuroendocrine hormones
and coagulation factors the next morning at 6 am. For
logistical reasons and reasons of patient care, blood
was collected non-fasting in 12 cases and not at 6 am
in 46 cases. Specific collection times were between 1
am and 5 am (n = 14), at 6 am (n = 144), between 7
am and 8 am (n = 13), between 9 am and 1 pm (n =
10), and between 2 pm and 6 pm (n = 9). Collection
time (all p-values > 0.64) and fasting state (all
p-values > 0.05) were not significantly associated with
circulating levels of any neuroendocrine hormone or
coagulation factor.
Measures
Sleep problems
To rate the risk of OSA, we applied a slightly modi-
fied version of the STOP questionnaire that is a tool
to screen patients for OSA, asking for snoring (S);
tiredness (T), observed (O) breathing cessations dur-
ing sleep; and high blood pressure (P) [42]. The
STOP questionnaire has been validated in patients
with CHD [43] and in German [44]. The STOP ques-
tionnaire is particularly sensitive to identify patients
with more severe forms of OSA [45], including in
CHD patients [43]. Specific questions in our study
(slight modifications from the original tool) asked
about a history of snoring (irrespective of its loud-
ness); history of breathing cessations while sleeping
(although not necessarily observed); being often fa-
tigued after sleep or while awake (sparing sleepiness);
and history of hypertension (sparing treatment). Pa-
tients answering “yes” to at least two of these four
questions were classified with a “high OSA risk”, and
all others with a “low OSA risk” [42]. To verify the
accuracy of the STOP screening tool to a certain ex-
tent, we also inquired about a positive history of sleep
apnea, predicting that patients who confirmed would
largely fall into the group with a high OSA risk. We
also asked patients whether they lived with someone
to account for the fact that household members often
notice and communicate signs of sleep-disordered
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breathing. Patients identified with a high OSA risk
were not treated for a presumed sleep disorder during
their acute hospitalization.
Sleep difficulties in terms of insomnia symptoms in
the previous 4 weeks were inquired with the 4-item Jen-
kins Sleep Scale with questions about difficulties initiat-
ing sleep, frequent awakenings during the night,
difficulties maintaining sleep, and non-restorative sleep
(i.e., feeling tired and worn out in the morning after a
usual night’s sleep) [46]. Response alternatives (scores)
are: not at all (0), 1–3 days (1), 4–7 days (2), 8–14 days
(3), 15–21 days (4), and 22–31 days (5), yielding an
average total score of all sleep difficulties between 0
and 5. Lower scores are indicative of better sleep qual-
ity. For illustrative purposes, patients were categorized
in those with poor (sore > 2) vs. good (score ≤ 2) sleep.
Cronbach’s alpha was 0.70 in the present study, sug-
gesting acceptable internal consistency of the scale.
Neuroendocrine hormones
Serum COR (nmol/L) was determined with an
electro-chemiluminescence immunoassay on a Cobas
analyzer (Roche Diagnostics, Switzerland) at the Insti-
tute of Clinical Chemistry, Inselspital, Bern University
Hospital, Switzerland. EPI and NEPI concentrations
were quantified in EDTA plasma by high-pressure
liquid chromatography using electrochemical detection
[47] at the Laboratory for Stress Monitoring, Göttingen,
Germany (inter−/intra-assay coefficients of variation
< 10%; limit of detection 10 pg/mL). Undetectable EPI
levels (n = 16) were assigned half the limit of detec-
tion (5 pg/mL).
Coagulation factors
Following a strict in-house protocol to ensure adequate
preanalytical conditions, all coagulation factors were de-
termined in citrate plasma at the haemostasis laboratory,
Inselspital, Bern University Hospital, Switzerland. Fi-
brinogen measurements (g/L) were performed according
to the Clauss method (Dade® Thrombin, Dade Behring,
Liederbach, Germany). Plasma D-dimer levels (ng/mL)
were determined with a quantitative sandwich enzyme
immunoassay (VIDAS-D-Dimer, bioMérieux, Geneva,
Switzerland), and from June 2015 on, with a
particle-based immunoturbidimetric assay (Innovance®
D-Dimer; Siemens AG, Munich, Germany). A highly sig-
nificant correlation (Passing Bablock regression analysis:
r = 0.952) between D-dimer values assessed with these
two methods has previously been demonstrated, suggest-
ing that their analytical performance is equally good
[48]. Von Willebrand factor antigen concentration (IU/
dL) was determined with vWF Ag® Kit (Siemens AG,
Munich, Germany), an immunoturbidimetric method
using polystyrene-based antibodies against VWF.
Covariates
In order to avoid overfitting of multivariate models, we
included a selection of 16 potentially relevant predictors
that might be confounders of the relationship between
sleep problems and neuroendocrine measures and
coagulation factors. We selected these covariates a priori
based on the literature and on theoretical assumptions.
Demographic factors
Age and gender were abstracted from hospital charts.
Socioeconomic status was based on the highest educa-
tion level (high: high school graduation/matura, univer-
sity graduation, including applied sciences; medium:
apprenticeship or vocational school; low: lower than
apprenticeship or vocational school) [49].
Comorbidities
We calculated the Charlson comorbidity index that
provides an estimate of future mortality across several
diseases [50]. Information on high cholesterol, hyper-
tension, diabetes either with or without end organ dam-
age, and lifetime depression was obtained through
history taking.
Health behaviors
Patients disclosed their weight and height for the calcu-
lation of the body mass index. Smoking status was
assessed in terms of current, former and never smokers,
and physical activity (“that makes you sweat”) in terms
of the average frequency per week. Regarding alcohol
consumption, we categorized patients into abstainers,
moderate drinkers, and heavy drinkers (> 21 drinks/week
for men, > 14 drinks/week for women).
Cardiac-related variables
These included the type of MI (STEMI/non-STEMI),
previous MI (yes/no), and the number of coronary arter-
ies with stenosis ≥50%. As an objective marker of MI
severity, we calculated the Global Registry of Acute Cor-
onary Events (GRACE) risk score from eight variables
obtained at hospital admission: age, heart rate, systolic
blood pressure, creatinine, Killip class, cardiac arrest,
ST-segment deviation, and elevated cardiac enzymes
[51]. The GRACE score is a robust predictor of the
cumulative risk of death or death and recurrent MI from
admission to 6 months after discharge [51].
Acute distress
The intensity of perceived distress during MI was
assessed with three numeric rating scales (scores 0–10)
for “pain intensity (during MI)”, “fear of dying (until
admission to the coronary care unit)” and “making sor-
rows and feeling helpless (when being told about having
MI)” [37]. These measures were previously shown to
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predict CVD-related hospital readmissions in ACS pa-
tients after a 3-year follow-up [52]. The added sum score
of the three numeric rating scales was divided by three
to yield a severity index of acute distress.
Data analysis
Data were analyzed using SPSS 23.0 for Windows (SPSS
Inc., Chicago, IL) with level of significance at p < 0.05.
For technical and logistic reasons (e.g., early discharge of
patients), EPI and NEPI were missing in 45 patients,
COR in 16 patients, fibrinogen in 14 patients, and
D-dimer and VWF in 15 patients each. Due to lacking
information, the GRACE risk score could not be com-
puted for 18 patients. Seven or less values were missing
for all other measures. We replaced all missing values
with the expectation maximization algorithm to make
use of all the available information from the total sample
of 190 study participants. Supporting the adequacy of this
approach, the strength and significance of the associations
between OSA risk and COR (r = − 0.16, p = 0.043; n = 170)
and between sleep difficulties and both fibrinogen (r =
0.16, p = 0.032; n = 172) and NEPI (r = − 0.18, p = 0.036; n
= 141) in the patients with complete data for these mea-
sures were similar to those shown in the result section for
the whole sample. Values of neuroendocrine hormones
and coagulation factors were log-transformed before
analysis.
Pearson correlation analysis was used to estimate
the univariate relationship between two variables.
Multivariate regression analysis was employed to
identify whether OSA risk (categorical variable: high
vs. low) and sleep difficulties (continuously scaled
variable) were independently associated with neuroen-
docrine hormones and coagulation factors, after
controlling for demographics, comorbidity, health be-
haviors, and cardiac-related variables, all entered in
one block. If the total sleep difficultly scale showed a
significant association, we computed post hoc analyses
on each individual item. Finally, to test for a possible
joint effect of OSA risk and sleep difficulties on
outcomes, we additionally entered the interaction
between the STOP score and the sleep difficulties
score total into the regression equation. We allowed a
maximum of 19 independent predicting variables to
protect against model overfitting. Cook’s distance and
variance inflation factor, respectively, were used to
verify the absence of influential outliers in the set of
predictor variables and critical multicollinearity be-
tween two predictor variables, respectively.
We did not adjust p-values for multiple comparisons be-
cause of the pre-established primary hypothesis of a signifi-
cant association of sleep problems with neuroendocrine
and coagulation measures, and because of the risk of deem-
ing truly important differences non-significant in a still
nascent field of research [53]. However, partial correlation
coefficients (rp) from the regression output were used to
interpret effect sizes as small (0.1), medium (0.3), or large
(0.5), irrespective of p-values [54].
Results
Patient characteristics
Table 1 shows the characteristics of the 190 patients,
all of Caucasian ethnicity. The majority of participants
were well-educated men with a first-time STEMI and
living together with someone. The Charlson index
indicated low comorbidity; nevertheless, a history of
hypertension and high cholesterol were reported by
every other patient, and a history of depression by
almost 30%. According to the GRACE score, the
median (inter-quartile range) risk of 6-month death
was 5% (3–9). Regarding health behaviors, patients
were on average overweight, and a substantial portion
were current smokers and physically inactive. Defin-
ing the group of poor sleepers, a total of 52 (27.4%)
patients reported sleep difficulties on more than 7
days in the previous 4 weeks. A total of 77 (40.5%)
patients could be identified with a high OSA risk; 15
(78.9%) of the 19 patients with a history of sleep
apnea were in this group. Living with someone was
not associated with OSA risk (p = 0.98), so it was not
used as a covariate. The type of drugs delivered at
admission and glucocorticoid use did not significantly
differ between patients with high versus low OSA risk
(all p-values > 0.06).
Unadjusted associations among sleep, neuroendocrine
and coagulation measures
There were several significant bivariate relationships
between sleep problems, neuroendocrine and coagula-
tion measures. High OSA risk was associated with
more sleep difficulties (r = 0.20, p = 0.006), with fre-
quent nighttime awakenings (r = 0.30, p < 0.001) and
nonrestorative sleep (r = 0.19, p = 0.011) driving this
relationship. High OSA risk was also associated with
lower COR levels (r = − 0.17, p = 0.022), and more
sleep difficulties were associated with higher fibrino-
gen levels (r = 0.14, p = 0.048), with difficulties initiat-
ing sleep driving this relationship (r = 0.22, p = 0.003).
Further expected direct associations were seen among
all stress hormones (EPI and NEPI: r = 0.51; EPI and
COR: r = 0.30; NEPI and COR: 0.29; p-values < 0.001)
and among all coagulation factors (fibrinogen and
D-dimer: r = 0.35; fibrinogen and VWF; r = 0.38;
D-dimer and VWF: r = 0.38; p-values < 0.001). Direct as-
sociations also emerged for NEPI with D-dimer (r = 0.17,
p = 0.020) and VWF (r = 0.16, p = 0.033) levels, and be-
tween COR and fibrinogen levels (r = 0.21, p = 0.004).
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Independent associations of sleep measures with
neuroendocrine hormones
Table 2 shows the fully adjusted multivariate model for
the levels of neuroendocrine hormones. Compared to
patients with low OSA risk, those with high OSA risk had
significantly lower levels for all three hormones. Figure 1
shows absolute values of these group differences. More
sleep difficulties (continuously scaled) were also signifi-
cantly associated with lower NEPI levels (absolute values
illustrated in Fig. 2 for poor vs. good sleepers). The rela-
tionship between sleep difficulties and NEPI was driven by
difficulties initiating (rp = − 0.15, p = 0.049) and maintain-
ing (rp = − 0.20, p = 0.008) sleep. Moreover, there was no
significant interaction between OSA risk and sleep diffi-
culties for stress hormones (p-values > 0.36).
Independent associations of sleep measures with
coagulation factors
Table 3 shows the fully adjusted multivariate model for
the three coagulation factors. More sleep difficulties
were associated with greater fibrinogen levels (absolute
values illustrated in Fig. 2 for poor vs. good sleepers),
with difficulties initiating sleep driving this relationship
(rp = 0.25, p = 0.001). Risk of OSA was not significantly
associated with any coagulation factor. Likewise, there
was no significant interaction between OSA risk and
sleep difficulties for coagulation factors (p-values > 0.35).
Role of stress hormones in the relation between sleep
and coagulation factors
The positive association of sleep difficulties with fibrino-
gen levels was virtually unchanged when EPI (rp = 0.16,
Table 1 Demographic and clinical characteristics of the 190
study participants
Age, yrs., M (SD) 59.9 (11.2)
Sex (men), n (%) 157 (82.6)
Education level
High, n (%) 36 (18.9)
Medium, n (%) 136 (71.6)
Low, n (%) 18 (9.5)
Living with someone, n (%) 138 (72.6)
Charlson comorbidity index, M (SD) 1.80 (1.20)
Positive history of hypertension, n (%) 98 (51.6)
Positive history of high cholesterol, n (%) 86 (45.3)
Positive history of depression, n (%) 54 (28.4)
Body mass index, kg/m2, M (SD) 27.7 (4.6)
Smoking status
Current smoker, n (%) 83 (43.7)
Former smoker, n (%) 50 (26.3)
Never smoker, n (%) 57 (30.0)
Alcohol consumption (drinks per week)
Abstainers, n (%) 33 (17.4)
Moderate drinkers, n (%) 147 (77.4)
Heavy drinkers, n (%) 10 (5.3)
Physical activity (number of times per week)
3–7, n (%) 49 (25.8)
1–2, n (%) 52 (27.4)
< 1, n (%) 89 (46.8)
Previous myocardial infarction, n (%) 20 (10.5)
Previous percutaneous coronary intervention 27 (14.2)
Previous coronary artery bypass surgery 5 (2.6)
Type of confirmed acute infarction
ST-elevation myocardial infarction, n (%) 136 (71.6)
Non-ST-elevation myocardial infarction, n (%) 54 (28.4)
Major coronary arteries with stenosis ≥50%
(number), M (SD)
1.93 (0.86)
Left ventricular ejection fraction
(angiography), %, M (SD)
47. 6 (11.8)
Vasopressant drugs at admission
Epinephrine, n (%) 9 (4.7)
Norepinephrine, n (%) 6 (3.2)
Dobutamine, n (%) 8 (4.2)
Dopamine, n (%) 1 (0.5)
Antithrombotic therapy at admission
Aspirin, n (%) 190 (100)
Clopidogrel, n (%) 57 (30.0)
Prasugrel, n (%) 99 (52.1)
Ticagrelor, n (%) 80 (42.1)
Fondaparinux, n (%) 154 (81.1)
Table 1 Demographic and clinical characteristics of the 190
study participants (Continued)
Unfractioned heparin, n (%) 145 (76.3)
Low molecular weight heparin, n (%) 13 (6.8)
Bivalirudin, n (%) 2 (1.1)
Abciximab, n (%) 46 (24.2)
Thrombolysis, n (%) 2 (1.1)
Beta-blocker therapy at admission, n (%) 173 (91.1)
Regular use of glucocorticoids, n (%) 13 (6.8)
Global Registry of Acute Coronary Events risk
score, M (SD)
107 (27)
Acute distress during myocardial infarction, M (SD) 6.23 (1.40)
Sleep difficulties total, M (SD) 1.53 (1.29)
Difficulties initiating sleep, M (SD) 1.24 (1.62)
Nighttime awakenings, M (SD) 2.53 (2.10)
Difficulties maintaining sleep, M (SD) 1.17 (1.68)
Nonrestorative sleep, M (SD) 1.17 (1.67)
High risk of obstructive sleep apnea, n (%) 77 (40.5)
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p = 0.043), NEPI (rp = 0.16, p = 0.031) and COR (rp =
0.15, p = 0.055) were separately added to the model in
Table 3. Neuroendocrine hormones were not signifi-
cantly predictive of fibrinogen (p-values > 0.06), D-dimer
(p-values > 0.07) and VWF (p-values > 0.37) levels, inde-
pendently of all other covariates. Also, OSA risk
(p-values > 0.27) and sleep difficulties (p-values > 0.11)
showed no significant interaction with neuroendocrine
hormones for any coagulation factor.
Discussion
In patients admitted with acute MI, we found a high risk
of OSA to be associated with decreased levels of EPI,
NEPI, and COR, compared to when OSA risk was low,
independent of covariates. Sleep difficulties in terms of
insomnia symptoms were also independently associated
with low NEPI levels, although not with EPI and COR
levels. Less evidence was found for an independent rela-
tionship between sleep problems and coagulation
factors. Whereas insomnia symptoms were associated
with higher levels of fibrinogen, although not with
D-dimer and VWF, OSA risk did not show a significant
association with any coagulation factor. The size of these
associations was similar to that observed for several
covariates with neuroendocrine and coagulation out-
comes, including the prognostic GRACE score, implying
not only statistical, but also clinical significance with
small-to-moderate effects of sleep problems.
In our sample, 40.5% of patients had a high OSA risk,
a prevalence similar to previous studies showing that
close to a half of patients with ACS have moderate or
severe OSA (apnea-hypopnea index ≥15) [55]. Also com-
parable to a previous study showing that 37.3% of hospi-
talized patients with ACS have clinically relevant
insomnia symptoms [56], 27.4% of our patients were
poor sleepers. In agreement with previous studies on
CVD outcomes [34], we did not observe joint effects
between OSA risk and insomnia symptoms for neuroen-
docrine hormones and coagulation factors. However,
concurring with a high prevalence of OSA among in-
somnia patients and vice versa [32], we found a signifi-
cant association between OSA risk and insomnia
symptoms with frequent awakenings and non-restorative
sleep driving this association. As we adjusted for an
overlap between OSA risk and insomnia symptoms, we
may interpret that in the setting of acute MI, neuroen-
docrine and coagulation abnormalities differ substan-
tially between high OSA risk and insomnia symptoms
Table 2 Multivariate relations between sleep problems and neuroendocrine measures
Entered variables Epinephrine Norepinephrine Cortisol
Partial corr. P Partial corr. P Partial corr. P
Age −0.183 0.016 0.050 0.516 −0.087 0.254
Male sex −0.079 0.302 0.080 0.295 −0.031 0.690
Education −0.092 0.230 −0.003 0.970 −0.051 0.504
Charlson index −0.240 0.001 −0.126 0.098 −0.111 0.147
Hypertension history 0.159 0.037 0.088 0.247 0.139 0.068
High cholesterol history 0.130 0.089 −0.070 0.357 − 0.002 0.978
Depression history 0.070 0.360 0.054 0.479 0.007 0.928
Body mass index −0.053 0.489 0.178 0.019 0.101 0.187
Smoking −0.047 0.541 −0.021 0.786 0.030 0.693
Alcohol consumption 0.026 0.731 −0.126 0.098 0.025 0.747
Physical activity −0.149 0.051 −0.031 0.688 0.043 0.572
Previous MI 0.140 0.067 0.001 0.994 0.074 0.333
ST-elevation MI 0.150 0.049 0.172 0.024 0.081 0.289
Stenotic coronary arteries 0.074 0.334 0.116 0.130 0.232 0.002
GRACE risk score 0.234 0.002 0.131 0.085 0.157 0.039
Acute distress 0.210 0.006 0.170 0.025 0.029 0.706
Sleep difficulties −0.054 0.482 −0.172 0.024 0.094 0.217
High risk of OSA −0.185 0.015 −0.150 0.049 −0.251 0.001
Model statistic R2 = 0.295
F18,171 = 3.97
P < 0.001
R2 = 0.212
F18,171 = 2.55
P = 0.001
R2 = 0.174
F18,171 = 2.00
P = 0.012
Linear regression model with all variables entered in one block. Significant correlation coefficients (Partial corr.) and P-values are given in bold
GRACE Global Registry of Acute Cardiac Events, MI myocardial infarction, OSA obstructive sleep apnea
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and even between individual insomnia symptoms. We
particularly found difficulties in initiating sleep to be sig-
nificantly associated with NEPI and fibrinogen, and diffi-
culties maintaining sleep also with NEPI, whereas
waking up during the night and nonrestorative sleep
showed no association with neuroendocrine hormones
and coagulation factors whatsoever.
Increased fibrinogen levels in acute MI patients
with more severe insomnia symptoms is compatible
with a prothrombotic state, one mechanism that may
possibly increase the risk of recurrent atherothrombo-
tic events [21]. In addition to having rheological and
hemostatic properties, fibrinogen is also an inflamma-
tory molecule (i.e., an acute phase reactant), and in-
flammation and sleep disturbances are reciprocally
linked with each other [57]. However, as we measured
fibrinogen only once, but inquired about insomnia
symptoms covering the preceding 4 weeks, we are un-
able to make any causal inferences. For instance, it is
possible that insomnia symptoms were already associ-
ated with elevated fibrinogen before MI and/or even
a contributing factor to MI onset, although exagger-
ated fibrinogen production during the acute phase
could also have occurred in those with more severe
insomnia symptoms. Clearly, our finding in fibrinogen
needs replication, as we did not observe a relation
between insomnia symptoms and the other two pro-
thrombotic markers. Future studies should also in-
clude measures of impaired fibrinolysis, particularly
plasminogen activator inhibitor-1 [16, 19].
Regarding neuroendocrine dysregulation, low en-
dogenous COR levels in CHD patients with high OSA
risk could result in less curtailing of vascular inflamma-
tion and atherosclerosis progression, respectively [58].
Indeed, low cortisol levels at admission were previously
shown to predict early death in patients with acute MI
[59]. Likewise, low catecholamine levels, found in those
with high OSA risk and more sleep difficulties in our
study, are implied in increased systemic inflammation
[60]. Moreover, in OSA, due to the accompanying SNS
hyperactivity, beta-2-adrenergic receptors are desensi-
tized [61], a mechanism that may result in blunted
beta-2-adrenergic receptor-mediated anti-inflammatory
effects of catecholamines [60]. As coagulation activa-
tion relates to catecholamine and cortisol activity [30,
31], comparably low SNS and HPA activation in rela-
tion to sleep problems may help to explain why neuro-
endocrine dysregulation was no associated with
coagulation factors in patients with high OSA risk and
insomnia symptoms, respectively.
That patients with OSA might not mount an appropri-
ate stress response to ACS could not only have
Fig. 1 Risk of obstructive sleep apnea and mean values of neuroendocrine measures. The bar graphs illustrate the significant differences in
epinephrine (p = 0.015), norepinephrine (p = 0.049) and cortisol (p = 0.001) levels between subjects with high (n = 77) vs. low (n = 113) risk of
obstructive sleep apnea (OSA), expressed as geometric mean values with 95% confidence interval. Adjustments were made for age, sex,
education, Charlson comorbidity index, positive history of hypertension/high cholesterol/depression, body mass index, smoking, alcohol
consumption, physical activity, previous myocardial infarction (MI), ST-segment MI, number of stenotic coronary arteries, Global Registry of Acute
Coronary Events risk score, acute distress, and sleep difficulties
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deleterious consequences for cardiac prognosis, as there
is data from animal models to suggest that chronic inter-
mittent hypoxia is a potentially adaptive stimulus for the
myocardium in OSA [62]. One study in humans found
more severe OSA to be associated with less cardiac in-
jury during non-fatal ACS, proposing that ischemic pre-
conditioning due to chronic intermittent hypoxia could
be a possible explanation [63]. Although the involved
physiological mechanisms are still elusive, there may be
pro-angiogenic and anti-oxidant effects of intermittent
hypoxia [62, 63]. For instance, as increased sympathetic
tone and elevated catecholamine levels in OSA might be
associated with increased reactive oxygen species
production [64]. A lower sympathoadrenal response in
the setting of ACS might result in less oxidative stress
and myocardial damage, respectively.
Our study has several limitations worth mentioning.
Most importantly, the lack of objective measures of
sleep architecture, sleep duration and sleep apnea test-
ing does not allow us to draw firm conclusions. To bet-
ter differentiate between effects of OSA risk and
insomnia symptoms, polysomnography or the add-
itional inclusion of validated screening tools, such as
the Berlin questionnaire and the Epworth Sleepiness
Scale would have yielded data that are more reliable.
We were particularly unable to tease apart influences of
obstructive versus central sleep apnea that is prevalent
in ACS. Moreover, objective short sleep duration is an
important factor driving activation of the stress system
and cardiometabolic morbidity in patients with insom-
nia [65]. However, it should also be mentioned that the
acute cardiac situation influences sleep macro- and
microarchitecture [66], which can complicate the diag-
nostic process. The STOP screening questionnaire is
not very sensitive and specific for moderate-to-severe
sleep-disordered breathing in CHD [42], but also in
other disorders [42, 67] and in population-based studies
[45]. A high sensitivity to detect more severe forms of
OSA in patients with coronary artery bypass surgery
was associated with low specificity [42], which increases
the risk of false positives. The STOP questionnaire does
not allow a firm assessment of OSA severity. Follow-up
sleep studies would have been necessary for this pur-
pose. It is not clear how the modified STOP question-
naire influenced its sensitivity and specificity. The
omission of loudness of snoring may have overesti-
mated the prevalence of patients classified with high
OSA risk. Nonetheless, the majority of patients who re-
ported a history of sleep apnea were in this group, sug-
gesting our slightly modified STOP tool showed
clinically useful sensitivity. Although time of blood col-
lection did not significantly relate to coagulation and
neuroendocrine measures, given their circadian vari-
ation, the difference in the time of assessment is a
limitation. Although we applied an established method
to replace missing data, the fact that 24% of patients
missed catecholamine measures is a further limitation.
We controlled for a range of important covariates, but
residual confounding through for instance combined
effects of emergency medications remains a possibility.
This weakens the interpretation of the relationships which
only emerged as significant in the covariate-adjusted ana-
lyses. In turn, non-significant results must be interpreted
with caution, as we did not perform a power calculation for
this ancillary sleep study. Body mass index, a driver of neu-
roendocrine and coagulation measures, was self-reported.
Although we controlled for acute distress during MI, the
Fig. 2 Sleep difficulties and mean values of neuroendocrine and
coagulation measures. The bar graphs illustrate the significant
differences in norepinephrine (p = 0.010) and fibrinogen
(p = 0.003) levels between subjects with poor sleep (i.e., sleep
difficulties on more than 7 days in the previous 4 weeks; n = 52)
and those with good sleep (n = 138), expressed as geometric
mean values with 95% confidence interval. Adjustments were
made for age, sex, education, Charlson comorbidity index,
positive history of hypertension/high cholesterol/depression,
body mass index, smoking, alcohol consumption, physical
activity, previous myocardial infarction (MI), ST-segment MI,
number of stenotic coronary arteries, Global Registry of Acute
Coronary Events risk score, acute distress, and risk of obstructive
sleep apnea
von Känel et al. BMC Cardiovascular Disorders          (2018) 18:213 Page 9 of 12
specifics of our sample with substantially distressed patients
need to be considered when generalizing the findings to
other cohorts of ACS patients. Distressed patients may have
over-reported sleep difficulties in their effort to make sense
of the situation. However, about 70% of patients experience
at least moderate distress and fear of dying during ACS
[68]. As is common in ACS studies, less than 20% of our
patients were women, which precluded sex-stratified ana-
lyses, which might result in different findings for women
and men [10, 11].
Conclusions
In patients admitted with acute MI, high OSA risk and
insomnia symptoms might differently affect neuroendo-
crine and coagulation activity. While a high OSA risk
was associated with neuroendocrine dysregulation, indi-
cating SNS and HPA axis hypoactivity, insomnia symp-
toms, particularly problems initiating or maintaining
sleep, showed a relation with reduced SNS activity and
a prothrombotic state. Low cortisol and catecholamine
levels might result in less curtailing of vascular inflam-
mation, and elevated fibrinogen levels might evoke a
prothrombotic state, with such pathophysiology helping
to explain adverse outcome of MI patients with sleep prob-
lems. In turn, the finding of lower neuroendocrine
hormones in patients with acute MI and a high OSA risk
may also inform further studies to better understand poten-
tially cardioprotective mechanisms of chronic intermittent
hypoxia.
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